Status: Recruiting
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
This study is designed to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in participants with haematologic malignancies.
Participants needed: 161
Trial details
Phase: Phase 1, Phase 2Age: 12+Biological sex: AllType: InterventionalSponsor: AstraZenecaUpdated: Jun 24, 2026Locations: 37
Eligibility criteria
Adequate adult (ECOG) or adolescent (Karnofsy or Lanksy) Performance Score asses... [+22]
Any significant laboratory finding or any severe and uncontrolled medical condit... [+32]